The present invention provides a novel method for producing natural killer (NK) cells, which enables production of a large amount of high-quality NK cells easily, inexpensively, and safely in a short period of time from pluripotent stem cells. Specifically, a method for producing NK cells is provided, including
(1) a step of forming pluripotent stem cell spheres having an average particle size of not less than 200 μm in a first medium;
(2) a step of inducing the pluripotent stem cell spheres formed in step (1) into a cell population including hematopoietic progenitor cells by three-dimensional culture using a second medium; and
(3) a step of inducing the cell population including hematopoietic progenitor cells obtained in step (2) into a cell population including NK cells by three-dimensional culture using a third medium,
wherein the steps (1) to (3) are performed by a perfusion culture method.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
The present invention provides methods for producing, from pluripotent stem cells, natural killer (NK) cells or precursor cells thereof. The methods are: a method which is characterized by comprising a) a step for inducing hematopoietic progenitor cells (HPCs) from pluripotent stem cells in vitro, b) a step for amplifying the HPCs in vitro, and c) a step for inducing, from the HPCs, NK cells or precursor cells thereof in vitro, and which is characterized in that a histone methyltransferase and/or an allyl hydrocarbon receptor (AHR) is inhibited in one or more of steps a)-c); and a method which comprises (1) a step for forming, in a first culture medium, pluripotent stem cell spheres having an average particle size of 200 µm or more, (2) a step for inducing a cell population including HPCs through three dimensional culturing of the pluripotent stem cell spheres obtained in step (1) by using a second culture medium containing a histone methyltransferase inhibitor and/or an AHR antagonist, and (3) a step for inducing a cell population including NK cells or precursor cells thereof through three dimensional culturing of the cell population including the HPCs obtained in step (2) by using a third culture medium containing the histone methyltransferase inhibitor and/or the AHR antagonist, and in which one or more of steps (1)-(3) are performed through perfusion culturing, and preferably steps (1)-(3) are performed through continuous perfusion culturing.
The present invention provides a pluripotent stem cell expressing the following (a) and (b):
(a) an exogenous gene encoding CC chemokine receptor 2 type B(CCR2B)
(b) an exogenous gene encoding CC chemokine ligand 19 (CCL19), or an NK cell derived from the pluripotent stem cell or a progenitor cell thereof.
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
The present invention provides a novel method for producing natural killer (NK) cells, which enables production of a large amount of high-quality NK cells easily, inexpensively, and safely in a short period of time from pluripotent stem cells. Specifically, a method for producing NK cells is provided, including (1) a step of forming pluripotent stem cell spheres having an average particle size of not less than 200 pm in a first medium; (2) a step of inducing the pluripotent stem cell spheres formed in step (1) into a cell population including hematopoietic progenitor cells by three-dimensional culture using a second medium; and (3) a step of inducing the cell population including hematopoietic progenitor cells obtained in step (2) into a cell population including NK cells by three-dimensional culture using a third medium, wherein the steps (1) to (3) are performed by a perfusion culture method.
The invention is directed to producing large numbers of cells using hollow fiber bioreactor technology. The cells are non-embryonic stem, non-germ cells that can be characterized by one or more of the following: extended replication in culture and markers of extended replication, such as telomerase, markers of pluripotentiality, and broad differentiation potential, without being transformed.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
PRODUCTION AND CRYOPRESERVATION METHOD FOR LYMPHOCYTES, CLEANSING LIQUID AND CRYOPRESERVATION LIQUID FOR SAME, AND PREPARATION OF LYMPHOCYTES FOR TRANSPLANTATION FROM CRYOPRESERVED LYMPHOCYTES
The present invention provides: a lymphocyte cleansing method that involves cleansing lymphocytes with a bicarbonate ion–containing physiological aqueous solution; a lymphocyte cryopreservation method that involves suspending and freezing lymphocytes obtained by means of the lymphocyte cleansing method in a cryopreservation liquid that contains a physiological aqueous solution; a lymphocyte cleansing liquid that contains a bicarbonate ion–containing physiological aqueous solution; a lymphocyte cryopreservation liquid that contains a bicarbonate ion–containing physiological aqueous solution, dextran, glucose, DMSO, and human serum albumin; a lymphocyte-containing composition that contains the cryopreservation liquid and lymphocytes treated with a bicarbonate ion–containing physiological aqueous solution; and a kit for preparing lymphocytes for transplantation that includes the lymphocyte-containing composition and a diluent for transplantation that contains a bicarbonate ion–containing physiological aqueous solution.
Provided is a vial rack, which has a massive portion made of a metal having good thermal conductivity as the main body, to be applied to a gas-cooling type freezer. The massive portion of the vial rack has one or more holes for inserting a vial. The gas-cooling type freezer cools the massive portion of the vial rack, which is placed in a cooling chamber with the vial inserted, with a cold gas. The massive portion thus cooled cools the vial and a cell suspension inside the vial through the inner surface of the hole. The vial rack of the present invention has the massive portion as the main body and, therefore, is suitable for cooling with a gas.
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (Japon)
Inventeur(s)
Inamori, Masakazu
Hino, Motohiro
Amimoto, Naoki
Tatsumi, Rie
Ikeda, Kazuhiro
Taniguchi, Hideki
Okamoto, Satoshi
Abrégé
The present invention provides a method for mass producing cell aggregates such as artificial organoids through an approach that differs entirely from previous methods. Specifically, provided is a method for producing cell aggregates that includes a step in which a mixture of mesenchymal stem cells, vascular endothelial cells, and organ cells are filled into microfibers, and the mixture is suspension cultured to form cell aggregates.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
The present invention provides compositions and methods for culturing cells and preparing sheets and three-dimensional arrangements of cells that can be used for tissue repair. The invention also relates to methods of treatment using the compositions.
The invention provides a method for producing a retinal pigment epithelial cell by (1) maintaining and/or expanding human pluripotent stem cells comprising culturing the human pluripotent stem cells in the absence of a feeder cell in a medium comprising a factor for maintaining an undifferentiated state, (2) a first step for culturing the maintained and/or expanded human pluripotent stem cells in a medium comprising a MEK inhibitor in the absence of feeder cells for a period of not less than 2 days and not more than 30 days, wherein the culture condition in the first step is a condition sufficient for inducing gene expression of at least one eye field transcription factor, and (3) a second step for culturing the cells obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The present invention provides a new natural killer (NK) cell production method capable of mass-producing safe and high-quality NK cells from pluripotent stem cells with ease and at a low cost in a short period of time. Specifically, provided is an NK cell production method characterized by comprising: (1) a step for forming, in a first medium, pluripotent stem cell spheres having an average particulate size of at least 200 μm; (2) a step for inducing the pluripotent stem cell spheres formed in step (1) into a cell population including hematopoietic progenitor cells by three-dimensional culture using a second medium; and (3) a step for inducing the cell population including the hematopoietic progenitor cells obtained in step (2) into a cell population including NK cells by three-dimensional culture using a third medium. The method is characterized in that steps (1) to (3) are performed by perfusion culturing.
The present invention provides a highly functional hypoimmunogenic cell, namely, a hypoimmunogenic human cell
(1) lacking an endogenous gene encoding an α chain of human leukocyte antigen (HLA) class Ia,
(2) lacking an endogenous gene encoding HLA class II or an expression regulator thereof,
(3) containing an exogenous gene encoding an α chain of HLA class Ib,
(4) containing an exogenous gene encoding human PD-L1, and
(5) containing an exogenous gene encoding human PD-L2.
The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2).
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
14.
GENE-MODIFIED PLURIPOTENT STEM CELL, IMMUNOCOMPETENT CELL DERIVED THEREFROM, METHOD FOR PRODUCING SAID CELLS, AND USE THEREOF
The present invention provides: pluripotent stem cells expressing (a) an exogenous gene encoding CC chemokine receptor type 2B (CCR2B) and (b) an exogenous gene encoding CC chemokine ligand 19 (CCL19); NK cells derived from said pluripotent stem cells; or precursor cells thereof.
The present invention provides: pluripotent stem cells expressing (a) an exogenous gene encoding CC chemokine receptor type 2B (CCR2B) and (b) an exogenous gene encoding CC chemokine ligand 19 (CCL19); NK cells derived from said pluripotent stem cells; or precursor cells thereof.
An apparatus for cryostorage and manipulation of a plurality of container units includes a cryochamber having a cryo-access port. The cryochamber is electrically cooled at cryogenic temperatures. A unit holder is located inside the cryochamber and is configured to hold a plurality of container units. A user access area is provided for selectively permitting access to a chosen container unit by an authenticated user who has been authenticated by the apparatus. A motive grasper is provided for selectively removing the chosen container unit from the cryochamber through the cryo-access port, and selectively placing the chosen container unit into the user access area.
F25D 11/04 - Dispositifs autonomes déplaçables associés à des machines frigorifiques, p. ex. réfrigérateurs ménagers adaptés spécialement pour le stockage des produits surgelés
B01L 7/00 - Appareils de chauffage ou de refroidissementDispositifs d'isolation thermique
B25J 21/00 - Enceintes à dispositifs de manipulation intégrés
F25D 25/04 - Introduction, port ou déchargement des produits à refroidir par transporteurs
F25D 29/00 - Disposition ou montage de l'appareillage de commande ou de sécurité
The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Cells for research purposes; stem cells for scientific
purposes; stem cells, other than for medical or veterinary
purposes. Cells for medical use; cell preparations for the treatment
of diseases and disorders; pharmaceutical preparations,
other than agricultural chemicals and medicinal alcoholic
beverages. Custom processing of human cells, not for medical purposes. Cultured cell bank services for medical transplantation;
stem cell bank services; processing of human cells and stem
cells, for medical purposes; custom processing of human
cells, for medical purposes.
19.
Stem Cell Aggregates and Methods for Making and Using
The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.
The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MPACs, in children, for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.
A61K 31/4353 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxis and that caused by insufficient blood supply. In some further particulars the invntion relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children, for example, and to the treatment of cortical infants and stroke with MAPCs in adults, for example.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 31/4353 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques
The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
The present invention provides high-performance hypoimmunogenic cells, specifically hypoimmunogenic human cells that (1) lack an endogenous gene encoding the a-chain of human leukocyte antigen (HLA) class Ia, (2) lack an endogenous gene encoding HLA class II or an expression regulator thereof, (3) include an exogenous gene encoding the a-chain of HLA class Ib, (4) include an exogenous gene encoding human PD-L1, and (5) include an exogenous gene encoding human PD-L2.
The present invention provides high-performance hypoimmunogenic cells, specifically hypoimmunogenic human cells that (1) lack an endogenous gene encoding the α-chain of human leukocyte antigen (HLA) class Ia, (2) lack an endogenous gene encoding HLA class II or an expression regulator thereof, (3) include an exogenous gene encoding the α-chain of HLA class Ib, (4) include an exogenous gene encoding human PD-L1, and (5) include an exogenous gene encoding human PD-L2.
Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
Medical machines, namely, medical apparatus in the nature of
a cryogenic storage and delivery apparatus specially adapted
for cryogenic freezing, thawing and dispensing biologic
product for medical purposes. Cryogenic system for medical purposes for use in hospital
pharmacies in the nature of a medical freezer for cooling,
storage, thawing and dispensing of pharmaceutical and
biologic products; cryogenic system for pharmaceutical and
biologic product storage use, namely, a cooling apparatus
for medical storage purposes; cryogenic refrigerators for
medical use, namely, cryogenic refrigeration and heating
apparatus for freezing, storage, thawing and dispensing
purposes; cryogenic freezers for medical storage purposes;
freezers for cryogenic storage for use in medical and
hospital fields.
Medical machines, namely, medical apparatus in the nature of
a cryogenic storage and delivery apparatus specially adapted
for cryogenic freezing, thawing and dispensing biologic
product for medical purposes. Cryogenic system for medical purposes for use in hospital
pharmacies in the nature of a medical freezer for cooling,
storage and dispensing device for cryogenic storing and
preserving, thawing and dispensing of pharmaceutical and
biologic products; cryogenic system for pharmaceutical and
biologic product storage use, namely, a cooling apparatus
for medical storage purposes; cryogenic refrigerators for
medical use, namely, cryogenic refrigeration and heating
apparatus for freezing, storage, thawing and dispensing
purposes; cryogenic freezers for medical storage purposes;
freezers for cryogenic storage for use in medical and
hospital fields.
Medical machines, namely, medical apparatus in the nature of
a cryogenic storage and delivery apparatus specially adapted
for cryogenic freezing, thawing and dispensing biologic
product for medical purposes. Cryogenic system for medical purposes for use in hospital
pharmacies in the nature of a medical freezer for cooling,
storage, thawing and dispensing of pharmaceutical and
biologic products; cryogenic system for pharmaceutical and
biologic product storage use, namely, a cooling apparatus
for medical storage purposes; cryogenic refrigerators for
medical use, namely, cryogenic refrigeration and heating
apparatus for freezing, storage, thawing and dispensing
purposes; cryogenic freezers for medical storage purposes;
freezers for cryogenic storage for use in medical and
hospital fields.
(1) Medical machines, namely, medical apparatus in the nature of a cryogenic storage and delivery apparatus specially adapted for cryogenic freezing, thawing and dispensing biologic product for medical purposes.
(2) Cryogenic system for medical purposes for use in hospital pharmacies in the nature of a medical freezer for cooling, storage, thawing and dispensing of pharmaceutical and biologic products; cryogenic system for pharmaceutical and biologic product storage use, namely, a cooling apparatus for medical storage purposes; cryogenic refrigerators for medical use, namely, cryogenic refrigeration and heating apparatus for freezing, storage, thawing and dispensing purposes; cryogenic freezers for medical storage purposes; freezers for cryogenic storage for use in medical and hospital fields.
(1) Medical machines, namely, medical apparatus in the nature of a cryogenic storage and delivery apparatus specially adapted for cryogenic freezing, thawing and dispensing biologic product for medical purposes.
(2) Cryogenic system for medical purposes for use in hospital pharmacies in the nature of a medical freezer for cooling, storage, thawing and dispensing of pharmaceutical and biologic products; cryogenic system for pharmaceutical and biologic product storage use, namely, a cooling apparatus for medical storage purposes; cryogenic refrigerators for medical use, namely, cryogenic refrigeration and heating apparatus for freezing, storage, thawing and dispensing purposes; cryogenic freezers for medical storage purposes; freezers for cryogenic storage for use in medical and hospital fields.
32.
Apparatus and method for cryostorage and manipulation of a plurality of container units
An apparatus for cryostorage and manipulation of a plurality of container units includes a cryochamber having a cryo-access port. The cryochamber is electrically cooled at cryogenic temperatures. A unit holder is located inside the cryochamber and is configured to hold a plurality of container units. A user access area is provided for selectively permitting access to a chosen container unit by an authenticated user who has been authenticated by the apparatus. A motive grasper is provided for selectively removing the chosen container unit from the cryochamber through the cryo-access port, and selectively placing the chosen container unit into the user access area.
F25D 11/04 - Dispositifs autonomes déplaçables associés à des machines frigorifiques, p. ex. réfrigérateurs ménagers adaptés spécialement pour le stockage des produits surgelés
B01L 7/00 - Appareils de chauffage ou de refroidissementDispositifs d'isolation thermique
B25J 21/00 - Enceintes à dispositifs de manipulation intégrés
F25D 25/04 - Introduction, port ou déchargement des produits à refroidir par transporteurs
F25D 29/00 - Disposition ou montage de l'appareillage de commande ou de sécurité
33.
Method for transferring cellular medicine using a cellular medicine transfer system
A cellular medicine transfer system includes: an adapter for a cellular medicine container including a first flow channel and a second flow channel through each of which a liquid and cells can flow; a cellular medicine container to which the adapter is attached, and in which a cellular medicine to be transferred is stored; an administration medium storage container that communicates with the first flow channel, and in which an administration medium is stored; a collection container for collecting a cellular medicine, that communicates with the second flow channel of the adapter; and a powering device that imparts motive power for transferring the administration medium from the administration medium storage container through the first flow channel to the cellular medicine container, and for transferring the cellular medicine and the administration medium from the cellular medicine container through the second flow channel to the collection container.
Medical machines, namely, medical apparatus in the nature of a cryogenic storage and delivery apparatus specially adapted for cryogenic freezing, thawing and dispensing biologic product for medical purposes Cryogenic system for medical purposes for use in hospital pharmacies in the nature of a medical freezer for cooling, storage and dispensing device for cryogenic storing and preserving, thawing and dispensing of pharmaceutical and biologic products; Cryogenic system for pharmaceutical and biologic product storage use, namely, a cooling apparatus for medical storage purposes; Cryogenic refrigerators for medical use, namely, cryogenic refrigeration and heating apparatus for freezing, storage, thawing and dispensing purposes; Cryogenic freezers for medical storage purposes; Freezers for cryogenic storage for use in medical and hospital fields
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Adjuvants for medical purposes; cells for medical use; cell
preparations for the treatment of diseases and disorders;
pharmaceutical preparations. Medical apparatus and instruments. Research and development in the field of cells; research and
development of pharmaceuticals and medical supplies;
research and development services relating to medicines;
testing, inspection or research of pharmaceuticals,
cosmetics or foodstuffs.
Medical machines, namely, medical apparatus in the nature of a cryogenic storage and delivery apparatus specially adapted for cryogenic freezing, thawing and dispensing biologic product for medical purposes Cryogenic system for medical purposes for use in hospital pharmacies in the nature of a medical freezer for cooling, storage and dispensing device for cryogenic storing and preserving, thawing and dispensing of pharmaceutical and biologic products; Cryogenic system for pharmaceutical and biologic product storage use, namely, a cooling apparatus for medical storage purposes; Cryogenic refrigerators for medical use, namely, cryogenic refrigeration and heating apparatus for freezing, storage, thawing and dispensing purposes; Cryogenic freezers for medical storage purposes; Freezers for cryogenic storage for use in medical and hospital fields
Medical machines, namely, medical apparatus in the nature of a cryogenic storage and delivery apparatus specially adapted for cryogenic freezing, thawing and dispensing biologic product for medical purposes Cryogenic system for medical purposes for use in hospital pharmacies in the nature of a medical freezer for cooling, storage and dispensing device for cryogenic storing and preserving, thawing and dispensing of pharmaceutical and biologic products; Cryogenic system for pharmaceutical and biologic product storage use, namely, a cooling apparatus for medical storage purposes; Cryogenic refrigerators for medical use, namely, cryogenic refrigeration and heating apparatus for freezing, storage, thawing and dispensing purposes; Cryogenic freezers for medical storage purposes; Freezers for cryogenic storage for use in medical and hospital fields
38.
MULTIPOTENT ADULT PROJENITOR CELLS FOR TREATMENT OF ICH
A61K 35/36 - PeauSystème pileuxOnglesGlandes sébacéesCérumenÉpidermeCellules épithélialesKératinocytesCellules de LangerhansCellules ectodermiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Adjuvants for medical purposes; cells for medical use; biological cell preparations for the treatment of diseases and disorders, namely, ophthalmic, central nervous system, respiratory, cardiovascular, liver, kidney, pancreatic, oncological, urological, and peripheral artery related diseases and disorders, as well as type 1 and type 2 diabetes, gynecological disease and stroke; pharmaceutical preparations for the prevention or treatment of ophthalmic, central nervous system, respiratory, cardiovascular, liver, kidney, pancreatic, oncological, urological, and peripheral artery related diseases and disorders, as well as type 1 and type 2 diabetes, gynecological disease and stroke Medical apparatus and instruments, namely, instruments and syringes for the regeneration of stem cells for medical purposes, excluding any electrical pulsing technology instruments; Medical apparatus and instruments, namely, instruments and syringes for medical use for administration or transplanting of stem cells or cells differentiated from iPS cells, excluding any electrical pulsing technology instruments; prosthetic tissues for parietal, visceral and vascular use; Medical apparatus and instruments, namely, syringes for medical purposes for injections for administration or transplanting of stem cells or cells differentiated from iPS cells, excluding any electrical pulsing technology instruments; Medical apparatus and instruments, namely, syringes for medical purposes for injections for the regeneration of stem cells for medical purposes, excluding any electrical pulsing technology instruments; eye testing machines and apparatus; Medical apparatus and instruments, namely, instruments and syringes for treating of ophthalmic, central nervous system, respiratory, cardiovascular, liver, kidney, pancreatic, oncological, and gynecological diseases and disorders, as well as type 1 and type 2 diabetes and stroke, and for administration or transplanting of stem cells or cells differentiated from iPS cells, excluding any electrical pulsing technology instruments; and Medical apparatus and instruments, namely, instruments and syringes for treating of ophthalmic, central nervous system, respiratory, cardiovascular, liver, kidney, pancreatic, oncological, and gynecological diseases and disorders, as well as type 1 and type 2 diabetes and stroke, and for the regeneration of stem cells for medical purposes, excluding any electrical pulsing technology instruments Scientific and medical research and development in the field of cells; research and development of pharmaceuticals and medical apparatus and instruments for others; research and development services relating to medicines; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
stem cells, other than for medical or veterinary purposes; stem cells for research purposes; stem cells for scientific purposes. adjuvants for medical purposes; cells for medical use; cell preparations for the treatment of diseases and disorders; pharmaceutical preparations; stem cells for veterinary purposes. medical apparatus and instruments. research and development in the field of cells; research and development of pharmaceuticals and medical supplies; research and development services relating to medicines; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; laboratory services for the processing of human cells and the processing of cells for treatment. medical information.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
stem cells, other than for medical or veterinary purposes; stem cells for research purposes; stem cells for scientific purposes adjuvants for medical purposes; cells for medical use; biological cell preparations for the treatment of diseases and disorders, namely, ophthalmic, central nervous, respiratory, cardiovascular, liver, kidney, pancreatic, type 1 and type 2 diabetes, oncological, urological, peripheral artery, gynecological disease, and stroke; pharmaceutical preparations for the prevention or treatment of ophthalmic, central nervous, respiratory, cardiovascular, liver, kidney, pancreatic, type 1 and type 2 diabetes, oncological, urological, peripheral artery, gynecological disease, and stroke; stem cells for veterinary purposes medical apparatus and instruments for use in surgery, apparatus for the regeneration of stem cells for medical purposes, surgical instruments and apparatus, surgical and medical apparatus and instruments for use in general surgery, medical instruments for cutting tissue, needles for medical purposes, medicinal catheters, medical instruments for interstitial thermotherapy of biological tissue, prosthetic tissues for parietal, visceral and vascular use, artificial bones for implantation, syringes for medical purposes for injections, and eye testing machines and apparatus; medical apparatus and instruments for treating of ophthalmic, central nervous, respiratory, cardiovascular, liver, kidney, pancreatic, type 1 and type 2 diabetes, oncological, urological, gynecological disease, and stroke custom processing of human cells; processing of biological cells for medical treatment scientific and medical research and development in the field of cells; research and development of pharmaceuticals and medical apparatus and instruments for others; research and development services relating to medicines; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs medical information
42.
Method for producing retinal pigment epithelial cells
The present invention provides a production method of a retinal pigment epithelial cell containing the following steps:
(1) a first step for culturing a pluripotent stem cell in a medium containing at least one kind selected from the group consisting of an FGF receptor inhibitor and an MEK inhibitor for a period of not more than 30 days, and
(2) a second step for culturing the cell obtained in the first step in a medium containing at least one kind selected from the group consisting of a Rho signal transduction pathway inhibitor and an apoptosis inhibitor to form a retinal pigment epithelial cell. The method can produce retinal pigment epithelial cells from pluripotent stem cells more efficiently and conveniently.
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The present invention, in which RPE cells are suspended in a medium pharmaceutically acceptable as an ocular irrigating/washing solution and containing a poloxamer, achieves improvement of the post-thawing survival rate of cryopreserved RPE cells, improvement of the photoreceptor cell protection effect by RPE cell transplanted immediately after thawing, and prevention of loss of RPE cells in various steps from thawing to transplantation.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
Medical machines, namely, medical apparatus specially
adapted for cryogenic freezing, thawing and dispensing
biologic product for medical purposes; Cryogenic system for
medical purposes for use in hospital pharmacies in the
nature of a storage and dispensing device for cryogenic
storing and preserving, thawing and dispensing of
pharmaceutical and biologic products. Cryogenic system for pharmaceutical and biologic product
storage use; cryogenic refrigerators for medical use;
cryogenic freezers for medical storage purposes; freezers
for cryogenic preservation for use in medical and hospital
fields.
(1) Medical machines, namely, medical apparatus in the nature of a cryogenic storage and delivery apparatus specially adapted for cryogenic freezing, thawing and dispensing biologic product for medical purposes.
(2) Cryogenic system for medical purposes for use in hospital pharmacies in the nature of a medical freezer for cooling, storage and dispensing device for cryogenic storing and preserving, thawing and dispensing of pharmaceutical and biologic products; cryogenic system for pharmaceutical and biologic product storage use, namely, a cooling apparatus for medical storage purposes; cryogenic refrigerators for medical use, namely, cryogenic refrigeration and heating apparatus for freezing, storage, thawing and dispensing purposes; cryogenic freezers for medical storage purposes; freezers for cryogenic storage for use in medical and hospital fields.
The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
47.
ADAPTER FOR CELL DRUG VESSEL, MULTI-PASSAGE ADAPTER FOR CELL DRUG VESSEL, AND CELL DRUG TRANSFER SYSTEM AND TRANSFER METHOD USING SAME
A cell drug transfer system (10) comprises: an adapter (1) for a cell drug vessel, said adapter (1) comprising a first passage (11) and a second passage (12), both passages allowing the passage of liquids and cells therethrough; a cell drug vessel (2) to which the adapter (1) is installed and which accommodates a cell drug to be transferred; an administration medium accommodation vessel (3) which communicates with the first passage (11) and accommodates an administration medium; a retrieval vessel (4) which is for retrieving the cell drug and communicates with the second passage (12) comprised by the adapter (1); and a powering means (5) which provides power for transferring the administration medium from the administration medium accommodation vessel (3) to the cell drug vessel (2) via the first passage (11), and for transferring the cell drug and the administration medium from the cell drug vessel (2) to the retrieval vessel (4) via the second passage (12).
Medical machines, namely, medical apparatus in the nature of a cryogenic storage and delivery apparatus specially adapted for cryogenic freezing, thawing and dispensing biologic product for medical purposes Cryogenic system for medical purposes for use in hospital pharmacies in the nature of a medical freezer for cooling, storage and dispensing device for cryogenic storing and preserving, thawing and dispensing of pharmaceutical and biologic products; Cryogenic system for pharmaceutical and biologic product storage use, namely, a cooling apparatus for medical storage purposes; Cryogenic refrigerators for medical use, namely, cryogenic refrigeration and heating apparatus for freezing, storage, thawing and dispensing purposes; Cryogenic freezers for medical storage purposes; Freezers for cryogenic storage for use in medical and hospital fields
The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
50.
Immunomodulatory properties of MAPCs and uses thereof
Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 31/4353 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. The method of the present invention for producing retinal pigment epithelial cells includes the following steps:
(1) a first step for culturing a pluripotent stem cell in a medium comprising an FGF receptor inhibitor and/or an MEK inhibitor for a period of not more than 30 days, and
(2) a second step for culturing the cell obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
53.
METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS
The present invention provides a method for producing retinal pigment epithelial cells including the following steps: (1) a first step for culturing pluripotent stem cells for a period that does not exceed 30 days by using a medium containing at least one type of substance selected from a group consisting of FGF receptor inhibitors and MEK inhibitors; and (2) a second step for forming the retinal pigment epithelial cells by culturing the cells obtained in the first step by using a medium containing at least one type of substance selected from a group consisting of Rho-signaling-pathway inhibitors and apoptosis inhibitors. With said method, it is possible to produce the retinal pigment epithelial cells from pluripotent stem cells in a more efficient, simple manner.
The present invention provides a method for producing retinal pigment epithelial cells including the following steps: (1) a first step for culturing pluripotent stem cells for a period that does not exceed 30 days by using a medium containing at least one type of substance selected from a group consisting of FGF receptor inhibitors and MEK inhibitors; and (2) a second step for forming the retinal pigment epithelial cells by culturing the cells obtained in the first step by using a medium containing at least one type of substance selected from a group consisting of Rho-signaling-pathway inhibitors and apoptosis inhibitors. With said method, it is possible to produce the retinal pigment epithelial cells from pluripotent stem cells in a more efficient, simple manner.
+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1β, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
A61K 38/00 - Préparations médicinales contenant des peptides
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Cells for medical or clinical use; cells for medical or clinical use for treatment of diseases; stem cells for medical purposes; stem cells for veterinary purposes; surgical implants comprising living tissue grown from stem cells; biological tissue cultures for medical purposes; biological tissue cultures for veterinary purposes; biological preparations for the treatment of ophthalmic, central nervous, respiratory, or cardiovascular disease; biological preparations for veterinary purposes for the treatment of cancer, liver disease and immune system related disease; diagnostic preparations for medical and veterinary use; diagnostic reagents for medicinal use; veterinary diagnostic reagents; adjuvants for medical purposes; cytostatics for medical purposes; pharmaceutical preparations for activating cellular function for the treatment of cancer, liver disease and immune system related disease; sanitary preparations for medical use; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for ocular or intraocular surgery; collyrium; eye drops; pharmaceutical agents affecting the central nervous system; pharmaceutical preparations for the peripheral nervous system; cardiovascular agents for medical purposes; cardiovascular treatment preparations; cardiovascular pharmaceuticals; cardiovascular pharmaceutical preparations; respiratory stimulants; pharmaceutical products for treating respiratory diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; anti-inflammatories; pharmaceutical agents affecting digestive organs; pharmaceutical agents for treating physically caused lesions; opotherapy preparations; organotherapy preparations; gene therapy products, namely, genetically engineered tissues for transplant purposes; surgical implants comprised of living tissues; pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for use in the fields of anesthesia, oncology, urology and gynecology
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Stem cells for research purposes; stem cells for scientific purposes; stem cells, other than for medical or veterinary purposes; diagnostic reagents and preparations, except for medical or veterinary use; biological tissue cultures, other than for medical or veterinary purposes; biological preparations for use in cell cultures other than for medical or veterinary use; biological preparations for use in industry and science Medical apparatus and instruments for use in surgery; Apparatus for the regeneration of stem cells for medical purposes; Surgical instruments and apparatus; Surgical and medical apparatus and instruments for use in general surgery; Medical instruments for cutting tissue; Needles for medical purposes; Medicinal catheters; Medical instruments for interstitial thermotherapy of biological tissue; Prosthetic tissues for parietal, visceral and vascular use; Artificial bones for implantation; Syringes for medical purposes and for injections; Eye testing machines and apparatus; Medical apparatus and instruments for treating cardiovascular disease; Medical apparatus for use in treating respiratory disease Stem cell research services; Research and development services in the field of cytology; Research and development of vaccines and medicines; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; Chemical research; Cosmetics research; Biological research; Medical and scientific research, namely, conducting clinical trials for others
The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.
A61K 31/4353 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
According to the present invention wherein RPE cells are suspended in a medium that contains poloxamer and is pharmaceutically acceptable as an eye perfusion/washing liquid, the survival ratio of the RPE cells having been freeze-preserved and then thawed can be increased, the visual cell-protecting effect of the RPE cells transplanted immediately after thawing can be improved, and a loss in the RPE cells in steps from thawing to transplantation can be avoided.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
According to the present invention wherein RPE cells are suspended in a medium that contains poloxamer and is pharmaceutically acceptable as an eye perfusion/washing liquid, the survival ratio of the RPE cells having been freeze-preserved and then thawed can be increased, the visual cell-protecting effect of the RPE cells transplanted immediately after thawing can be improved, and a loss in the RPE cells in steps from thawing to transplantation can be avoided.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Stem cells for medical or clinical use; pharmaceutical
compositions comprising stem cells; pharmaceutical
compositions comprising stem cells for the treatment of
neurological, cardiovascular, orthopedic, inflammatory and
immune diseases, disorders, conditions and injuries, solid
organ transplantation and wound healing.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Stem cells for medical and clinical use; Stem cells for pharmaceutical purposes; Pharmaceutical compositions comprising stem cells for the treatment of ophthalmological diseases, disorders, conditions and injuries; pharmaceutical compositions comprising stem cells for the treatment of pulmonary diseases, disorders, conditions and injuries, namely, acute respiratory distress; Pharmaceutical compositions comprising stem cells for the treatment of neurological diseases, disorders, conditions and injuries, namely ischemic stroke, traumatic brain injury, neonatal hypoxic ischemia, spinal cord injury, multiple sclerosis, Parkinson's disease and hemorrhagic stroke; Pharmaceutical compositions comprising stem cells for the treatment of cardiovascular diseases, disorders, conditions and injuries; Pharmaceutical compositions comprising stem cells for the treatment of orthopedic diseases, disorders, conditions and injuries; Pharmaceutical compositions comprising stem cells for the treatment of inflammatory and immune diseases, disorders, conditions and injuries namely, inflammatory bowel disease, graft-versus-host disease, autoimmune disease, blood and immune system disorders; Pharmaceutical compositions comprising stem cells for use in solid organ transplantation and wound healing.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Stem cells for medical or clinical use; pharmaceutical compositions comprising stem cells; pharmaceutical compositions comprising stem cells for the treatment of neurological, cardiovascular, orthopedic, inflammatory and immune diseases, disorders, conditions and injuries, solid organ transplantation and wound healing
66.
METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS
The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. This method for producing retinal pigment epithelial cells comprises the following steps: (1) a first step of culturing pluripotent stem cells for a period not exceeding 30 days, in a medium including an FGF receptor inhibitor and/or a MEK inhibitor; and (2) a second step of forming retinal pigment epithelial cells by culturing the cells obtained in the first step, in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
67.
METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS
The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. This method for producing retinal pigment epithelial cells comprises the following steps: (1) a first step of culturing pluripotent stem cells for a period not exceeding 30 days, in a medium including an FGF receptor inhibitor and/or a MEK inhibitor; and (2) a second step of forming retinal pigment epithelial cells by culturing the cells obtained in the first step, in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
68.
Eye disease treatment agent, screening method therefor, and method for predicting rejection response associated with retinal pigment epithelial cell transplant
The present invention provides an agent for treating ophthalmic diseases and a screening method for an agent for treating ophthalmic diseases and the like. The present invention also provides a method for predicting rejection associated with transplantation of retinal pigment epithelial cell to patients with ophthalmic diseases.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
69.
Method for purification of retinal pigment epithelial cells
The present invention provides a method of purifying highly pure retinal pigment epithelial cells from a cell population obtained by induction of differentiation of pluripotent stem cells into retinal pigment epithelial cells, by a simple and easy operation in a short period. The purification method of the present invention includes a step of introducing a cell population containing retinal pigment epithelial cells obtained by differentiation induction of pluripotent stem cells on laminin or a fragment thereof on a filter, and obtaining a cell population that passed the filter.
Provided are a production method of retinal pigment epithelial (RPE) cells that improves differentiation induction efficiency of pluripotent stem cells into RPE cells, and can provide highly pure RPE cells by a simple and easy operation in a short period, a culture method of RPE cells that can stably grow and culture a cell, a toxicity/efficacy evaluation method using RPE cells useful for transplantation therapy, and a therapeutic drug for a retinal disease. The invention relates to a production method of RPE cells, comprising adhesion culture of human pluripotent stem cells using a culture substrate coated with a laminin-E8 fragment, a culture method of RPE cells, comprising adhesion culture of RPE cells using a culture substrate coated with a laminin-E8 fragment, a toxicity or efficacy evaluation method using RPE cells obtained by producing or culturing by the method, and a therapeutic drug for a retinal disease, containing the RPE cells.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
71.
Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the method, and methods for using the cells
The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype and cells that express a hepatic sinusoidal endothelial phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.
The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
73.
EYE DISEASE TREATMENT AGENT, SCREENING METHOD THEREFOR, AND METHOD FOR PREDICTING REJECTION RESPONSE ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL CELL TRANSPLANT
The present invention provides an eye disease treatment agent, a screening method for the eye disease treatment agent, and the like. The present invention also provides a method for predicting a rejection response that is associated with the transplant of retinal pigment epithelial cells to a patient suffering from an eye disease.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Stem cells for scientific purposes; Stem cells other than for medical or veterinary purposes; Stem cells for research purposes; Diagnostic reagents and preparations, except for medical or veterinary use; Biological preparation for use in cell cultures other than for medical or veterinary use. Veterinary preparations; Stem cells for medical purposes; Cellular function activating agents for medical purposes; Stem cells for veterinary purposes; Surgical implants grown from stem cells. Medical instruments for cutting tissue; Needles for medical purposes; Medicinal catheters; Medical instruments for interstitial thermotherapy of biological tissue; Prosthetic tissues for parietal use; Prosthetic tissues for visceral use; Artificial bones for implantation; Syringes for medical purposes and for injections. Medical services relating to the removal, treatment and processing of stem cells; Medical services relating to the removal, treatment and processing of human blood, umbilical cord blood, human cells, stem cells and bone marrow.
75.
METHOD OF PRODUCING RETINAL PIGMENT EPITHELIAL CELL
Provided are a method of producing retinal pigment epithelial cells, with which the differentiation-induction efficiency of retinal pigment epithelial cells from pluripotent stem cells can be improved and highly pure retinal pigment epithelial cells obtained in a short time through a simple operation; a culture method for retinal pigment epithelial cells with which the cells can be stably grown and cultured; a toxicity/drug efficacy evaluation method employing retinal pigment epithelial cells useful in transplant therapy; and a retinal disease therapeutic drug. The present invention pertains to a method of producing retinal pigment epithelial cells, including a step for adherent culture of human pluripotent stem cells using a culture substrate coated with laminin E8 fragments; a culture method for retinal pigment epithelial cells, including a step for adherent culture of retinal pigment epithelial cells using a culture substrate coated with laminin E8 fragments; a toxicity/drug efficacy evaluation method employing retinal pigment epithelial cells obtained through production or culture by the aforedescribed methods; and a retinal disease therapeutic drug containing the retinal pigment epithelial cells.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
Provided are a method of producing retinal pigment epithelial cells, with which the differentiation-induction efficiency of retinal pigment epithelial cells from pluripotent stem cells can be improved and highly pure retinal pigment epithelial cells obtained in a short time through a simple operation; a culture method for retinal pigment epithelial cells with which the cells can be stably grown and cultured; a toxicity/drug efficacy evaluation method employing retinal pigment epithelial cells useful in transplant therapy; and a retinal disease therapeutic drug. The present invention pertains to a method of producing retinal pigment epithelial cells, including a step for adherent culture of human pluripotent stem cells using a culture substrate coated with laminin E8 fragments; a culture method for retinal pigment epithelial cells, including a step for adherent culture of retinal pigment epithelial cells using a culture substrate coated with laminin E8 fragments; a toxicity/drug efficacy evaluation method employing retinal pigment epithelial cells obtained through production or culture by the aforedescribed methods; and a retinal disease therapeutic drug containing the retinal pigment epithelial cells.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
The present invention provides a method for purification of retinal pigment epithelial cells, with which high-purity retinal pigment epithelial cells can be obtained in short time by a simple procedure, from a cell group obtained through differentiation induction to retinal pigment epithelial cells from pluripotent stem cells. This purification method includes a step in which a cell group that contains retinal pigment epithelial cells obtained through differentiation induction of pluripotent stem cells on laminin or fragments thereof is introduced into a filter, and the cell group that has passed through the filter is obtained.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
The present invention provides a method for purification of retinal pigment epithelial cells, with which high-purity retinal pigment epithelial cells can be obtained in short time by a simple procedure, from a cell group obtained through differentiation induction to retinal pigment epithelial cells from pluripotent stem cells. This purification method includes a step in which a cell group that contains retinal pigment epithelial cells obtained through differentiation induction of pluripotent stem cells on laminin or fragments thereof is introduced into a filter, and the cell group that has passed through the filter is obtained.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Stem cells for research purposes; stem cells for research or scientific purposes; stem cells other than for medical or veterinary purposes; stem cells for clinical, medical, scientific or laboratory research. Pharmaceutical and veterinary preparations; medical and veterinary preparations and articles; live organs and tissues for surgical purpose; stem cells; stem cells for medical purposes; stem cells for veterinary purposes; surgical implants grown from stem cells [living tissues]; stem cells for clinical, medical or pharmaceutical use; stem cells for regenerative clinical, medical or pharmaceutical use. Medical and pharmacological research services; medical research; medical research services; biological research, clinical research and medical research; medical and pharmacological research services; analysis of human tissues for medical research; scientific investigations for medical purposes; scientific research for medical purposes in the area of diseases; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research, in particular clinical, medical and scientific research in the field of stem cells; extracting, processing, growing and inserting stem cells in the context of clinical, medical and scientific research; information, advisory, research and consultation services in relation to any of the aforesaid; any of the aforesaid also provided online via the Internet or any other electronic platform.
The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
81.
Use of Stem Cells to Reduce Leukocyte Extravasation
The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.
The invention is directed to methods for making cells in vitro that have an extra-embryonic endodermal precursor phenotype. The method involves culturing cells from blastocysts under specific defined conditions.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, undo dermal, and mesodermal embryonic germ layers, e.g., stem cells.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A01K 67/00 - Élevage ou obtention d'animaux, non prévus ailleursNouvelles races ou races modifiées d'animaux
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
86.
Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype and cells that express a hepatic sinusoidal endothelial phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.
+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1β, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
A61K 38/00 - Préparations médicinales contenant des peptides
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
90.
MAPC therapeutics without adjunctive immunosuppressive treatment
The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 31/4353 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
92.
Multipotent adult stem cells and methods for isolation
The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
93.
Multipotent adult stem cells and methods for isolation
The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
94.
Multipotent adult stem cells and methods for isolation
The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
95.
Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The invention provides methods for differentiating non-embryonic multipotent stem cells along the pancreatic lineage. The present invention further provides non-embryonic multipotent stem cells and progeny derived therefrom to provide pancreatic cells to a subject.
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
The present invention relates to methods of improving function in lung tissue by administering a population of multipotent adult progenitor cells (“MAPCs”) or differentiated progeny thereof.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
98.
Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
Described is a method of expanding human progenitor cells by suspension culturing under non-static conditions. The culturing method provides a three-dimensional space for the rapid expansion of desirable progenitors. By this method, a new compartment of multipotential progenitor cells has been identified, which give rise under differentiation conditions to progeny including osteoblasts, chondrocytes, myoblasts, adipocytes, and other non-hematopoietic cell types. Their use in cell and tissue-based engineering is described.
C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
G01N 33/567 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand utilisant un extrait de tissu ou d'organe comme agent de liaison
A01N 1/00 - Conservation de corps humains ou animaux, ou de parties de ceux-ci
100.
Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
